Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3048]

Comment: Targeted therapy ivosidenib in cholangiocarcinoma

Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK

Comment: Targeted therapy ivosidenib in cholangiocarcinoma ( Dr Angela Lamarca - The Christie NHS Foundation Trust, Manchester, UK )

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019

Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith

Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019 ( Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith )

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF...

Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona...

BEACON: Encorafenib plus cetuximab with or without binimetinib for BRAF V600E–mutant metastatic colorectal cancer ( Prof Josep Tabernero - Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, USA )

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and...

Prof George Sledge - Stanford Health Care, Stanford, USA

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Ovarian highlights from ESMO 2019

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain

Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

More from ecancer